Abstract：
OBJECTIVE: To evaluate the achievement of low-density lipoprotein cholesterol (LDLc) goals established by the 2019 European Guidelines for the Management of Dyslipidemias and 2021 Cardiovascular Disease Prevention Guidelines, describe the lipid-lowering treatment received, analyze the achievement of goals according to the lipid-lowering treatment received and study the factors associated with therapeutic success.
METHODS: Observational study that included 185 patients of both sexes aged 18 or over undergoing lipid-lowering treatment for primary or secondary prevention, attended at the Lipid Unit.
RESULTS: 62.1% of the patients had a very high cardiovascular risk (CVR) according to the 2019 guidelines, and 60.5% according to the 2021 guidelines. Of the total cases, 22.7% achieved adequate control of LDLc according to the 2019 guidelines and 20% according to the 2021 guidelines. 47.6% of the patients received very high intensity lipid-lowering treatment, and 14.1% received extremely high intensity lipid-lowering treatment. 76% of subjects with very high CVR on extremely high intensity lipid-lowering treatment achieved the therapeutic objectives of both guides. In the multivariate analysis, factors associated with therapeutic success were the presence of arteriosclerotic cardiovascular disease, the intensity of lipid-lowering treatment, diabetes mellitus, and low to moderate alcohol consumption.
CONCLUSIONS: Dyslipidemia control is improvable. High or extremely high intensity lipid-lowering treatments can contribute to optimizing control of patients with higher CVR.
METHODS: Observational study that included 185 patients of both sexes aged 18 or over undergoing lipid-lowering treatment for primary or secondary prevention, attended at the Lipid Unit.
RESULTS: 62.1% of the patients had a very high cardiovascular risk (CVR) according to the 2019 guidelines, and 60.5% according to the 2021 guidelines. Of the total cases, 22.7% achieved adequate control of LDLc according to the 2019 guidelines and 20% according to the 2021 guidelines. 47.6% of the patients received very high intensity lipid-lowering treatment, and 14.1% received extremely high intensity lipid-lowering treatment. 76% of subjects with very high CVR on extremely high intensity lipid-lowering treatment achieved the therapeutic objectives of both guides. In the multivariate analysis, factors associated with therapeutic success were the presence of arteriosclerotic cardiovascular disease, the intensity of lipid-lowering treatment, diabetes mellitus, and low to moderate alcohol consumption.
CONCLUSIONS: Dyslipidemia control is improvable. High or extremely high intensity lipid-lowering treatments can contribute to optimizing control of patients with higher CVR.
摘要：
目的：评估2019年欧洲血脂异常管理指南和2021年心血管疾病预防指南建立的低密度脂蛋白胆固醇（LDLc）目标的实现，描述接受的降脂治疗，根据接受的降脂治疗分析目标的实现，并研究与治疗成功相关的因素。
方法：观察性研究，包括185名年龄在18岁或以上的男女患者，接受降脂治疗以进行一级或二级预防，参加了脂质小组。
结果：根据2019年指南，62.1％的患者具有非常高的心血管风险（CVR），根据2021年指南，为60.5%。在所有案件中，根据2019年指南，22.7%实现了LDLc的充分控制，根据2021年指南，20%实现了LDLc的充分控制。47.6%的患者接受高强度降脂治疗,14.1%接受了极高强度降脂治疗。在极高强度降脂治疗中，CVR非常高的受试者中有76％达到了两个指南的治疗目标。在多变量分析中，与治疗成功相关的因素是动脉硬化性心血管疾病的存在，降脂治疗的强度，糖尿病,低到中度饮酒。
结论：血脂异常控制是可以改善的。高强度或极高强度降脂治疗可有助于优化对具有较高CVR的患者的控制。
方法：观察性研究，包括185名年龄在18岁或以上的男女患者，接受降脂治疗以进行一级或二级预防，参加了脂质小组。
结果：根据2019年指南，62.1％的患者具有非常高的心血管风险（CVR），根据2021年指南，为60.5%。在所有案件中，根据2019年指南，22.7%实现了LDLc的充分控制，根据2021年指南，20%实现了LDLc的充分控制。47.6%的患者接受高强度降脂治疗,14.1%接受了极高强度降脂治疗。在极高强度降脂治疗中，CVR非常高的受试者中有76％达到了两个指南的治疗目标。在多变量分析中，与治疗成功相关的因素是动脉硬化性心血管疾病的存在，降脂治疗的强度，糖尿病,低到中度饮酒。
结论：血脂异常控制是可以改善的。高强度或极高强度降脂治疗可有助于优化对具有较高CVR的患者的控制。
